Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UD TGFbetai NK Cells and Temozolomide in Melanoma Metastatic to the Brain
NCT05588453Phase 2Recruiting
- Sponsor
- Kari Kendra
- Start
- Mar 2023
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of transforming growth factor-beta-imprinted natural killer cells in melanoma, sponsored by Kari Kendra. Started Mar 2023; status: recruiting.
02
Drugs
transforming growth factor-beta-imprinted natural killer cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05588453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588453.